ZHOU Jian, ZHANG Chaoyang, SUN Wei, et al. Effects of miR-503 targeting TLR4 on drug resistance to docetaxel in prostate cancer[J]. China Oncology, 2020, 30(11): 858-864.
ZHOU Jian, ZHANG Chaoyang, SUN Wei, et al. Effects of miR-503 targeting TLR4 on drug resistance to docetaxel in prostate cancer[J]. China Oncology, 2020, 30(11): 858-864. DOI: 10.19401/j.cnki.1007-3639.2020.11.002.
Effects of miR-503 targeting TLR4 on drug resistance to docetaxel in prostate cancer
Background and purpose: In the standard chemotherapy for prostate cancer
docetaxel (DTX) resistance is one of the important causes of death in patients. However
the potential mechanism of DTX chemoresistance is still unclear. Therefore
this study aimed to explore the potential mechanism of DTX resistance in prostate cancer. Methods: A total of 40 patients with prostate cancer who received chemotherapy in the Wuhan Third hospital
including 20 patients with resistance and 20 patients with sensitivity to DTX
were enrolled
and the tumor tissues were collected during surgery. The resistant cells PC-3/DTX were PC-3 cells induced by DTX. Real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) was performed to detect the mRNA expressions of miR-503 and TLR4. Western blot was conducted to detect TLR4 protein expression. The interaction between miR-503 and TLR4 was determined by luciferase reporter assay. Cell viability and apoptosis were determined by methyl thiazolyl tetrazolium (MTT) assay and flow cytometry
respectively. Results: The expression of miR-503 was decreased (P=0.013)
while TLR4 was increased in the resistant tissues and cells (P=0.005 6). Overexpression of miR-503 suppressed cell viability
induced cell apoptosis
and inhibited expression of drug resistance-related protein MDR-1. Furthermore
overexpression of TLR4 reversed the effects of miR-503 overexpression. Conclusion: miR-503 targets TLR4 to regulate its expression
The application of prostate-specific antigen in prostate cancer early detection in Chinese population: a Meta-analysis
Challenges and directions of immune checkpoint inhibitors in the treatment of lung cancer
Related Author
WANG Baohua
SHA Yuting
HE Fengdie
WU Jing
WANG Jie
Related Institution
The National Center for Chronic and Noncommunicable Disease Control and Prevention
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College